Landos Biopharma (LABP) News Today → get a piece of the profit from this land (From True Market Insiders) (Ad) Free LABP Stock Alerts $22.47 +0.17 (+0.76%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 11, 2024 | businesswire.comLANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPMay 9, 2024 | investorplace.comLABP Stock Earnings: Landos Biopharma Misses EPS for Q1 2024April 26, 2024 | msn.comEx-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit OutlookApril 17, 2024 | msn.comLandos Biopharma (LABP) Price Target Increased by 154.20% to 12.96April 16, 2024 | prnewswire.comStockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVieApril 10, 2024 | marketbeat.comLandos Biopharma, Inc. (NASDAQ:LABP) Short Interest UpdateLandos Biopharma, Inc. (NASDAQ:LABP - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 4,900 shares, an increase of 345.5% from the March 15th total of 1,100 shares. Based on an average daily volume of 23,300 shares, the short-interest ratio is presently 0.2 days. Currently, 0.2% of the company's stock are short sold.April 3, 2024 | marketbeat.comLandos Biopharma, Inc. Expected to Earn Q1 2024 Earnings of ($0.88) Per Share (NASDAQ:LABP)Landos Biopharma, Inc. (NASDAQ:LABP - Free Report) - HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of Landos Biopharma in a note issued to investors on Monday, April 1st. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share ofApril 1, 2024 | marketbeat.comHC Wainwright Reiterates Neutral Rating for Landos Biopharma (NASDAQ:LABP)HC Wainwright reiterated a "neutral" rating and set a $20.42 price target (down previously from $50.00) on shares of Landos Biopharma in a report on Monday.March 27, 2024 | businesswire.comLANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPMarch 27, 2024 | finanznachrichten.deLandos Biopharma, Inc.: AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 27, 2024 | markets.businessinsider.comLeerink Partners Remains a Hold on Landos Biopharma (LABP)March 26, 2024 | prnewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Landos Biopharma, Inc - LABPMarch 26, 2024 | markets.businessinsider.comAbbVie To Acquire Landos Biopharma At $20.42/share In CashMarch 26, 2024 | bizjournals.comAbbVie to buy Landos Biopharma for $137 millionMarch 26, 2024 | finance.yahoo.comWhy Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?March 25, 2024 | investorplace.comWhy Is Landos Biopharma (LABP) Stock Up 168% Today?March 25, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Landos Biopharma, Inc. has obtained a Fair Price in its transaction with AbbVieMarch 25, 2024 | businesswire.comLABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to ShareholdersMarch 25, 2024 | reuters.comAbbVie to buy Landos to expand pipeline of immunity-related illnessesMarch 25, 2024 | prnewswire.comAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 25, 2024 | marketbeat.comTrading was temporarily halted for "LABP" at 08:03 AM with a stated reason of "News pending."March 25, 2024 | globenewswire.comAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 21, 2024 | investorplace.comLABP Stock Earnings: Landos Biopharma Misses EPS for Q4 2023March 21, 2024 | finanznachrichten.deLandos Biopharma, Inc.: Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 ResultsMarch 21, 2024 | benzinga.comRecap: Landos Biopharma Q4 EarningsMarch 21, 2024 | globenewswire.comLandos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 ResultsMarch 6, 2024 | benzinga.comXontogeny, LLC's Net WorthMarch 5, 2024 | finance.yahoo.comWill Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?January 10, 2024 | benzinga.comAmbrx Biopharma Stock (NASDAQ:AMAM) Dividends: History, Yield and DatesJanuary 8, 2024 | finance.yahoo.comLandos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis OrganisationNovember 22, 2023 | msn.comLandos’s NX-13 shows symptom relief in Phase Ib ulcerative colitis trialNovember 21, 2023 | finanznachrichten.deLandos Biopharma, Inc.: Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn's and ColitisNovember 21, 2023 | marketwatch.comLandos Biopharma Shares Rise 10% After Positive Trial Data for NX-13November 21, 2023 | finance.yahoo.comLandos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and ColitisNovember 9, 2023 | msn.comLandos Biopharma GAAP EPS of -$0.94November 9, 2023 | benzinga.comLandos Biopharma: Q3 Earnings InsightsNovember 9, 2023 | finance.yahoo.comLandos Biopharma Provides Company Update and Reports Third Quarter 2023 ResultsNovember 9, 2023 | finance.yahoo.comLandos Biopharma Provides Company Update and Reports Third Quarter 2023 ResultsNovember 1, 2023 | marketbeat.comTrading was temporarily halted for "LABP" at 09:11 AM with a stated reason of "LULD pause."October 23, 2023 | finance.yahoo.comLandos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific MeetingSeptember 22, 2023 | markets.businessinsider.comJonesTrading Sticks to Its Hold Rating for Landos Biopharma (LABP)September 19, 2023 | finance.yahoo.comLandos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 CongressSeptember 19, 2023 | finance.yahoo.comLandos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 CongressSeptember 14, 2023 | finance.yahoo.comLandos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial CellsAugust 9, 2023 | finanznachrichten.deLandos Biopharma, Inc.: Landos Biopharma Provides Business Update & Reports Second Quarter 2023 ResultsAugust 9, 2023 | seekingalpha.comSCPS Scopus BioPharma Inc.August 9, 2023 | finance.yahoo.comLandos Biopharma Provides Business Update & Reports Second Quarter 2023 ResultsAugust 9, 2023 | finance.yahoo.comLandos Biopharma Provides Business Update & Reports Second Quarter 2023 ResultsMay 31, 2023 | finance.yahoo.comLandos Biopharma to Present at the 2023 Jefferies Healthcare ConferenceMay 26, 2023 | finanznachrichten.deLandos Biopharma, Inc.: Landos Biopharma Announces 1-for-10 Reverse Stock Split Get Landos Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LABP and its competitors with MarketBeat's FREE daily newsletter. Email Address get a piece of the profit from this land (Ad)This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land. Click here to see my #1 investment for 2024. LABP Media Mentions By Week LABP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LABP News Sentiment▼0.000.42▲Average Medical News Sentiment LABP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LABP Articles This Week▼01▲LABP Articles Average Week Get Landos Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LABP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Leap Therapeutics News Celularity News Journey Medical News MediciNova News InflaRx News Marinus Pharmaceuticals News Lantern Pharma News Viveon Health Acquisition News SCYNEXIS News Aileron Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LABP) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Landos Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
